Colorectal Cancer Screening

The Problem:

Colorectal cancer is the 2nd leading cause of cancer-related deaths, resulting in over 50,000 deaths annually. Colorectal cancer’s high mortality rate is due, in part, to flaws in existing methodologies to screen for the disease. Colonoscopies are the gold standard for detection, but they require patients to take time off from work and to undergo an inconvenient bowel preparation, so many patients avoid them. On the other hand, existing noninvasive alternatives are unreliable due to low accuracy rates.

Our Solution:

Geneoscopy has used its platform technology to develop a stool-based, multi-target RNA biomarker panel that can accurately identify colorectal cancer by capturing the downstream effects of cancer-causing DNA mutations. The result is a diagnostic test that can improve colorectal cancer screening compliance, facilitate early-stage detection of colorectal cancer neoplasms, and reduce morbidity and mortality associated with the disease.

Noninvasive Procedure
Improved Patient Compliance
Low Cost
Better Outcomes

Metastatic, or stage IV colon cancers, have a 5-year relative survival rate of about 11%.

Overall, the lifetime risk of developing colorectal cancer is: about 1 in 21 (4.7%) for men and 1 in 23 (4.4%) for women

– American Cancer Society

Contact Us

Geneoscopy, LLC

4320 Forest Park Ave. Suite 303
Saint Louis, MO 63108
geneoscopy@gmail.com

Stay in the Know